Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 10,000 shares at $121.38 ($1.2M) on 2018-12-14, disclosed to the SEC on 2018-12-18.
Seasonal sale ($1.2M) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in December in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $120.23 | 627 | $75K | 6.2% |
| 2 | $120.23 | 627 | $75K | 6.2% |
| 3 | $121.38 | 4,373 | $531K | 43.8% |
| 4 | $121.38 | 4,373 | $531K | 43.8% |
| Total | $121.24 avg | 10,000 | $1.2M | 100% |
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |